4/16
06:01 pm
imux
Immunic (IMUX) was given a new $2.50 price target by Stifel Nicolaus.
Low
Report
Immunic (IMUX) was given a new $2.50 price target by Stifel Nicolaus.
4/15
08:00 am
imux
Immunic (IMUX) was downgraded by D. Boral Capital from "buy" to "hold".
Low
Report
Immunic (IMUX) was downgraded by D. Boral Capital from "buy" to "hold".
4/9
06:47 am
imux
Immunic to Participate in Scientific and Medical Conferences in April [TheStreet.com]
Medium
Report
Immunic to Participate in Scientific and Medical Conferences in April [TheStreet.com]
4/9
06:30 am
imux
Immunic to Participate in Scientific and Medical Conferences in April
Medium
Report
Immunic to Participate in Scientific and Medical Conferences in April
4/1
08:09 am
imux
Immunic regains compliance with Nasdaq minimum bid price requirement [Seeking Alpha]
Low
Report
Immunic regains compliance with Nasdaq minimum bid price requirement [Seeking Alpha]
4/1
07:01 am
imux
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement [Yahoo! Finance]
Low
Report
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement [Yahoo! Finance]
4/1
06:30 am
imux
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
Low
Report
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
3/31
09:13 am
imux
Immunic appoints biopharmaceutical executive Jon Congleton to board [Yahoo! Finance]
Medium
Report
Immunic appoints biopharmaceutical executive Jon Congleton to board [Yahoo! Finance]
3/31
06:47 am
imux
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton [Yahoo! Finance]
Low
Report
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton [Yahoo! Finance]
3/31
06:30 am
imux
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
Low
Report
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
3/24
08:03 am
imux
Immunic (IMUX) is now covered by Guggenheim. They set a "buy" rating and a $7.00 price target on the stock.
Low
Report
Immunic (IMUX) is now covered by Guggenheim. They set a "buy" rating and a $7.00 price target on the stock.
3/20
08:03 am
imux
Immunic, Inc. (IMUX) Announces European Patent Grant for Vidofludimus Calcium [Yahoo! Finance]
Low
Report
Immunic, Inc. (IMUX) Announces European Patent Grant for Vidofludimus Calcium [Yahoo! Finance]
3/20
06:58 am
imux
Immunic Conference: “Transformative” 2026 Ahead With Pivotal MS Data Due Late Year, NDA Next [Yahoo! Finance]
Low
Report
Immunic Conference: “Transformative” 2026 Ahead With Pivotal MS Data Due Late Year, NDA Next [Yahoo! Finance]
3/18
10:32 am
imux
Immunic Details Vidofludimus Calcium MS Strategy, Phase III Timeline at Leerink Conference [Yahoo! Finance]
Low
Report
Immunic Details Vidofludimus Calcium MS Strategy, Phase III Timeline at Leerink Conference [Yahoo! Finance]
3/10
12:20 pm
imux
Immunic secures European patent for MS drug candidate vidofludimus calcium [Yahoo! Finance]
Medium
Report
Immunic secures European patent for MS drug candidate vidofludimus calcium [Yahoo! Finance]
3/10
06:49 am
imux
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium [Yahoo! Finance]
Low
Report
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium [Yahoo! Finance]
3/10
06:30 am
imux
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
Low
Report
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
3/3
06:30 am
imux
Immunic to Participate in Investor Conferences in March
Low
Report
Immunic to Participate in Investor Conferences in March
3/2
08:03 am
imux
Immunic (IMUX) had its price target lowered by HC Wainwright from $8.00 to $5.00. They now have a "buy" rating on the stock.
Low
Report
Immunic (IMUX) had its price target lowered by HC Wainwright from $8.00 to $5.00. They now have a "buy" rating on the stock.
2/28
03:14 pm
imux
Immunic secures $400M to support late-stage MS trials - ICYMI [Yahoo! Finance]
Low
Report
Immunic secures $400M to support late-stage MS trials - ICYMI [Yahoo! Finance]
2/26
09:20 am
imux
Immunic sets stage for phase 3 MS data readout after $400M financing [Yahoo! Finance]
Low
Report
Immunic sets stage for phase 3 MS data readout after $400M financing [Yahoo! Finance]
2/26
06:39 am
imux
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
2/26
06:30 am
imux
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
Medium
Report
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
2/17
04:53 pm
imux
Immunic closes $200M private placement to fund late-stage MS trials [Yahoo! Finance]
Low
Report
Immunic closes $200M private placement to fund late-stage MS trials [Yahoo! Finance]
2/17
04:05 pm
imux
Immunic Announces Closing of Oversubscribed Private Placement Financing
Low
Report
Immunic Announces Closing of Oversubscribed Private Placement Financing